424B5 ·Filed May 18, 2026

GILD

GILEAD SCIENCES, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed4mo ago SEC0001104659-26-063199
Notable filing: 424B5
Actionable Insight • Neutral

Monitor Gilead's M&A pipeline — the $2.99B in net proceeds plus $4.7B term loan capacity signals potential for near-term acquisitions. The strong Q1 results and raised guidance provide fundamental support, but increased leverage warrants watching credit rating actions. No immediate catalyst for common equity from this debt offering alone.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
GILD ▲ +5.91% at T+60d
NEUTRAL call ✓ call won +5.91% · α vs SPY -0.11% · entry $130.43 → $138.14
Entry anchored
May 18, 2026
via day open
T+1d
+0.14%
call +0.14% · α -0.90%
$130.61
settled 5mo ago
T+5d
+2.44%
call +2.44% · α +0.15%
$133.62
settled 4mo ago
T+20d
-2.45%
call -2.45% · α -4.71%
$127.23
settled 4mo ago
T+60d
+5.91%
call +5.91% · α -0.11%
$138.14
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Gilead Sciences is issuing $3.0 billion in senior unsecured notes across four tranches (2028-2034), with net proceeds of approximately $2.99 billion for general corporate purposes including acquisitions and strategic transactions. The offering follows strong Q1 2026 results (product sales ex-Veklury up 8% YoY, raised full-year guidance) and comes alongside a $4.7 billion term loan facility, of which $1.1 billion was drawn pre-closing. For common equity holders, this is a neutral capital structure event — debt issuance increases leverage modestly but funds growth initiatives without equity dilution.

Key Facts

  • $3.0 billion aggregate principal amount of senior notes across four tranches: $500M 4.250% due 2028, $1.0B 4.400% due 2029, $1.0B 4.600% due 2031, $500M 4.900% due 2034
  • Net proceeds estimated at ~$2.99 billion after underwriting discounts and expenses
  • Proceeds to be used for general corporate purposes including acquisitions, investments, and strategic transactions
  • Pro forma cash and marketable securities increase from $8.6B to $12.7B; total debt rises from $22.2B to $26.3B
  • Q1 2026 product sales ex-Veklury increased 8% YoY to $6.8B; total revenue up 4% to $7.0B
  • Non-GAAP diluted EPS of $2.03 vs $1.81 YoY; full-year product sales guidance raised to $30.0-30.4B from $29.6-30.0B
  • Notes are senior unsecured, unrated in filing, and not listed on any exchange
  • Offering follows strong Q1 earnings (filed May 7, 2026) and a $4.7B term loan facility entered in April 2026

Financial Impact

Debt issuance of $3.0B increases total debt by ~13.5% from $22.2B to $26.3B; pro forma cash increases by ~47% to $12.7B; net leverage remains manageable given $2.5B quarterly operating cash flow

debtcashinterest expenseleverage

Risk Factors

  • Increased leverage from $22.2B to $26.3B could pressure credit ratings if not deployed accretively
  • Proceeds earmarked for acquisitions carry execution risk and potential value destruction
  • Fixed-rate notes expose Gilead to above-market interest costs if rates decline
  • Structural subordination to subsidiary debt (~$3.7B in subsidiary obligations)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
79% bullish (39 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001104659-26-063199
Document: tm2531124d2_ex-filingfees.htm0001104659-26-063199
Document: 0001104659-26-063199-index-headers.html0001104659-26-063199
Document: 0001104659-26-063199-index.html0001104659-26-063199
Document: 0001104659-26-063199.txt0001104659-26-063199
16 reports for GILD
Performance horizon
83% Hit rate 5 of 6 directional calls best @ T+60▲ +16.72%Jul 6, 2026
Filters
Rows
Reports for GILD — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
Insider Cluster
NEUTRAL ★ 2/10
$149.61 $149.05▼ −0.37%▼ −0.04%$144.74 (−3.26%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$145.68 $152.21▲ +4.48%▲ +4.22%$144.74 (−0.65%)
Aug 21, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$146.74 $152.67▲ +4.04%▲ +2.73%$144.74 (−1.36%)
Aug 18, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$147.60 $150.89▲ +2.23%▲ +4.18%$144.74 (−1.94%)
Aug 18, 2026
6w ago
Court Ruling
BULLISH ★ 7/10
$143.44 $147.68▲ +2.96%▲ +4.27%$144.74 (+0.91%)
Aug 13, 2026
7w ago
Court Ruling
BULLISH ★ 6/10
$138.14 $143.72▲ +4.04%▲ +5.79%$144.74 (+4.78%)
Aug 6, 2026
8w ago
S-3ASR
NEUTRAL ★ 2/10
$133.21 $151.00▲ +13.35%▲ +13.75%$144.74 (+8.66%)
Jul 21, 2026
10w ago
ANALYST-DOWNGRADE
BEARISH ★ 4/10
$130.28 $143.44▼ −10.10%▼ −7.54%$144.74 (−11.10%)
Jul 16, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$134.28 $138.33▲ +3.02%▼ −1.43%$144.74 (+7.79%)
Jul 6, 2026
12w ago
ANALYST-UPGRADE
BULLISH ★ 3/10
$129.61 $130.21▲ +0.46%▲ +1.03%$144.74 (+11.67%)
Showing 10 of 16

US Market Status

Market Closed — Opens Mon (64h 16m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access